Our findings suggest that FiBYL719 treatment can produce durable tumour-specific inhibition of the PI3K pathway without the emergence of chronic hyperglycaemia and hyperinsulinaemia that results in exhaustion of the insulin-producing β cells and compensatory augmentation of glucagon-producing α cells. The gene discussed is INS; the disease is neoplasm.